X4 Pharmaceuticals, Inc. / Fundamentals

    Income statement

    Net revenue
    €28.06M
    Cost of goods sold
    €4.77M
    Gross profit
    €23.29M
    SG&A expenses
    €47.39M
    R&D expenses
    €66.55M
    EBITDA
    -€80.67M
    D&A
    €462.29K
    EBIT
    -€90.65M
    Interest expenses
    €5.95M
    EBT
    -€87.01M
    Tax expenses
    €294.50K
    Net income
    -€87.30M

    Cash flow statement

    Net deferred tax
    €0.00
    Non-cash items
    -€6.72M
    Changes in working capital
    -€5.26M
    Operating cash flow
    -€93.57M
    Capex
    €113.86K
    Other investing cash flow
    -€2.57M
    Net investing cash flow
    -€3.92M
    Total cash dividends paid
    €0.00
    Issuance of common stock
    €4.78M
    Debt repayment
    €0.00
    Other financing cash flow
    €115.57K
    Net financing cash flow
    €4.94M
    Foreign exchange effects
    €113.00K
    Net change in cash
    -€91.77M
    Cash at end of period
    €34.26M
    Free cash flow
    -€93.45M

    Balance sheet

    Cash and cash equivalents
    €33.58M
    Cash and short-term investments
    €53.89M
    Total receivables
    €980.22K
    Inventory
    €2.71M
    Other current assets
    €4.86M
    Total current assets
    €62.44M
    Property, plant & equipment
    €2.48M
    Goodwill
    €14.85M
    Intangible assets
    €8.24M
    Long-term investments
    €686.59K
    Other non-current assets
    €1.33M
    Total non-current assets
    €27.59M
    Total assets
    €90.03M
    Accounts payable
    €6.60M
    Short-term debt
    €1.17M
    Other current liabilities
    €11.18M
    Total current liabilities
    €19.60M
    Long-term debt
    €697.71K
    Deferred tax liabilities
    €0.00
    Other non-current liabilities
    €66.34M
    Total non-current liabilities
    €67.03M
    Total liabilities
    €86.63M
    Common stock
    €6.85K
    Retained earnings
    -€462.99M
    Other equity
    -€118.14K
    Total equity
    €3.40M
    Total liabilities and shareholders' equity
    €90.03M

    Company information

    Market capitalization
    €9.04M
    Employees
    143
    Enterprise Value
    -€19.29M

    Company ratios

    Gross margin
    83.0%
    EBITDA margin
    -287.5%
    EBIT margin
    -323.1%
    EBT margin
    -310.1%
    Net margin
    -311.1%
    ROE
    -2,568.0%
    ROA
    -97.0%
    Asset turnover
    31.2%
    FCF margin
    -333.9%
    FCF yield
    -1,036.8%
    Efficiency ratio
    387.5%
    Net sales per employee
    €196.21K
    Net income per employee
    -€610.49K

    Notifications